AU Patent

AU2016350701B2 — CD80 extracellular domain polypeptides and their use in cancer treatment

Assigned to Five Prime Therapeutics Inc · Expires 2021-08-19 · 5y expired

What this patent protects

This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

USPTO Abstract

This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016350701B2
Jurisdiction
AU
Classification
—
Expires
2021-08-19
Drug substance claim
No
Drug product claim
No
Assignee
Five Prime Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.